A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease | Zendy

Harold C. Wiesenfeld | Zendy; Leslie A. Meyn | Zendy; Toni Darville | Zendy; Ingrid Macio | Zendy; Sharon L. Hillier | Zendy

Open Access

A Randomized Controlled Trial of Ceftriaxone and Doxycycline, With or Without Metronidazole, for the Treatment of Acute Pelvic Inflammatory Disease

Author(s) -

Harold C. Wiesenfeld,

Leslie A. Meyn,

Toni Darville,

Ingrid Macio,

Sharon L. Hillier

Publication year - 2020

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciaa101

Subject(s) - medicine , metronidazole , ceftriaxone , tolerability , doxycycline , pelvic inflammatory disease , placebo , anaerobic bacteria , gastroenterology , regimen , mycoplasma genitalium , surgery , antibiotics , adverse effect , chlamydia trachomatis , gynecology , microbiology and biotechnology , pathology , genetics , alternative medicine , bacteria , biology

Anaerobic organisms are important pathogens in acute pelvic inflammatory disease (PID). The currently recommended PID regimen of a single dose of ceftriaxone and doxycycline for 14 days has limited anaerobic activity. The need for broader anaerobic coverage is unknown and concerns have been raised about metronidazole tolerability.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research